Patterns and predictors of oral antipsychotic prescribing in adult patients with schizophrenia

Vadiei, Nina; El-Ali, Jasim; Delaune, Joss; Wild, Cecilia; Liu, Yi-Shao

doi:10.1016/j.rcsop.2022.100148

Cited by 2 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…APs are generally regarded as the first-line treatment for patients with schizophrenia and were given to the majority of these patients, although a sizable number of studies reported patients who received no dispensed APs. The frequency of AP use was 67-98.8% in schizophrenia patients in these studies [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. Most patients (52.3% to 90.9%) were on AP monotherapy [28][29][30][31]34,38,[40][41][42][43][44][45][46][47][48][49][50][51][52], except for five studies [27,[53][54][55][56].…”

Section: Antipsychotic Prescription Trends and Clinical Correlatesmentioning

confidence: 77%

“…Some patients with schizophrenia may be mildly ill or in remission from their illness, hence APs may not be used [36]. In addition, it is possible for studies to have incomplete data, coding errors, and reporting errors [28,39], leading to the possibility of patients not on any recorded APs.…”

Section: Discussionmentioning

confidence: 99%

“…Most studies reported greater SGA use (ranging from 31.2% to 93.1%) [19,28,29,38,39,55,57,[61][62][63][64][65][66][67][68][69][70] as compared to FGA (8.9% to 71.3%) [19,28,29,38,39,55,57,[61][62][63][64][65][66][67][68][69][70]. Prescription rates of FGA fell over the years (by 11-26.1%) [35,38,43,49,55,57,59,[68][69][70][71][72][73][74], except for one study [75].…”

Section: Antipsychotic Prescription Trends and Clinical Correlatesmentioning

confidence: 99%

“…Risperidone (16.3-44.8%) was the most prescribed oral AP in seven studies [19,27,38,39,63,67,68,76], or among the top few in other studies (12.5-69.2%) [25,31,32,45,46,61,[77][78][79]. Olanzapine (13.7-91.3%) [19,25,27,32,35,39,45,61,63,[77][78][79][80][81][82], quetiapine (7.6-17.8%) [25,32,35,39,79], aripiprazole (11.6-31.9%) [35,43] and haloperidol (17.9-62%) [31,32,38,51,61,68] were also frequently prescribed. Studies investigating trends in AP use reported that ziprasidone [83], olanzapine [49,78,80], and quetia...…”

Section: Antipsychotic Prescription Trends and Clinical Correlatesmentioning

confidence: 99%

“…There was a wide range of prescription rates for CLZ in both Europe and the US, ranging from 3-22.7% in Europe [25,27,29,31,32,35,40,45,58,79,80,85,107] and from 2-46.2% in the US [39,42,59,78,108]. In non-European countries, rates of CLZ use were 3.8% in Nepal [61], 66% in Uzbekistan [32], and 35% in New Zealand [49], 25% in Australia [52].…”

Section: Clozapine Usementioning

confidence: 99%

See 4 more Smart Citations

Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review

Ying,

Chew,

Wang

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

It is important to examine the psychotropic prescription practices in schizophrenia, as it can inform regarding changing treatment choices and related patient profiles. No recent reviews have evaluated the global neuropsychopharmacological prescription patterns in adults with schizophrenia. A systematic search of the literature published from 2002 to 2023 found 88 empirical papers pertinent to the utilization of psychotropic agents. Globally, there were wide inter-country and inter-regional variations in the prescription of psychotropic agents. Overall, over time there was an absolute increase in the prescription rate of second-generation antipsychotics (up to 50%), mood stabilizers (up to 15%), and antidepressants (up to 17%), with an observed absolute decrease in the rate of antipsychotic polypharmacy (up to 15%), use of high dose antipsychotic (up to 12% in Asia), clozapine (up to 9%) and antipsychotic long-acting injectables (up to 10%). Prescription patterns were mainly associated with specific socio-demographic (such as age), illness (such as illness duration), and treatment factors (such as adherence). Further work, including more evidence in adjunctive neuropsychopharmacological treatments, pharmaco-economic considerations, and examination of cohorts in prospective studies, can proffer insights into changing prescription trends relevant to different treatment settings and predictors of such trends for enhancement of clinical management in schizophrenia.

show abstract

Section: Antipsychotic Prescription Trends and Clinical Correlatesmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Antipsychotic Prescription Trends and Clinical Correlatesmentioning

confidence: 99%

Section: Antipsychotic Prescription Trends and Clinical Correlatesmentioning

confidence: 99%

Section: Clozapine Usementioning

confidence: 99%

See 3 more Smart Citations

Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review

Ying,

Chew,

Wang

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

show abstract

More than a Half-Century with Haloperidol: Glories, Disparities, and Use Today

Mills

2023

Issues in Mental Health Nursing

View full text Add to dashboard Cite

Patterns and predictors of oral antipsychotic prescribing in adult patients with schizophrenia

Cited by 2 publications

References 31 publications

Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review

Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review

More than a Half-Century with Haloperidol: Glories, Disparities, and Use Today

Contact Info

Product

Resources

About